Claris Lifesciences reported a consolidated net profit of Rs 141.44 crore for the year ended December 31, 2010, rise of 8.49%, year-on-year (YoY). Total income rose to Rs 626.68 crore for the period, compared to Rs 627.78 crore in the same period previous fiscal. The company launched five new products in 2010.
The US Food and Drug Administration (US FDA) had imposed a ban on Claris LifeSciences because some of its injectable drugs were contaminated with bacteria and fungus. Speaking to CNBC-TV18, Arjun Handa, managing director and CEO, Claris Lifesciences said."We have had very productive meeting with the US FDA and are hopeful of resolving the issue very soon. We donDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
